• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 14th July 2016

OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology

On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology Initiative (POI) as part of a wider research project being…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

On Tuesday 28th June 2016 OHE held a workshop on the topic of surrogate endpoints as predictors of overall survival in oncology. The workshop was commissioned by the Pharmaceutical Oncology Initiative (POI) as part of a wider research project being undertaken by OHE.

A clinical endpoint is an aspect of a patient’s clinical or health status that is measured to assess the benefit or harm of a treatment. Overall survival (OS) is the gold standard endpoint for clinical trials assessing the efficacy of cancer treatments in terms of their effects in improving length of life. However, measuring OS requires a large number of patients and long follow-up periods. This considerably increases the cost of development and delays patients’ access to new cancer drugs.

In response to this problem, various surrogate endpoints have been used in place of OS. Surrogates have the advantage that they can be assessed earlier than OS and require smaller patient populations.

Progression free survival (PFS) is the most commonly used surrogate in cancer. Regulatory decision-makers, such as the EMA and FDA, have used PFS as the basis for marketing approval of some new therapies. Bodies such as NICE, that advise on which aspects of healthcare may be covered by national health insurance, are concerned with both the effectiveness and cost-effectiveness implications of the use of surrogate endpoints. There is increasing concern in the scientific community regarding the validity of PFS as a surrogate of OS.

On Tuesday 28th of June 2016, the OHE organised a workshop aimed at discussing the statistical and health economics issues around the current approaches to extrapolating from PFS to OS. The workshop was attended by a range of participants including academics, representatives of the pharmaceutical industry and NICE.

During the workshop, Professor Rod Taylor, from the University of Exeter Medical School, described the trade-off between getting much faster results and at lower cost using a surrogate endpoint, but at the expense of a less certain eventual outcome. In addition, Dr Oriana Ciani, Postdoctoral Research Fellow in the University of Exeter Medical School and Research Fellow of the Università Commerciale L. Bocconi in Milan, discussed the implications and challenges for regulators, payers and triallists of the issues surrounding the validation of surrogates.

OHE’s Dr Karla Hernandez-Villafuerte presented the preliminary results of a systematic review that she is undertaking to identify the principal weaknesses and gaps in current methods and approaches for validating PFS as a surrogate of OS. OHE’s Dr Alastair Fischer presented an outline of modelling work conducted by Prof Marc Buyse which attempts to determine which surrogate endpoints can be validated and which of several surrogates is estimated to be the best. 

In general, presentations, discussions and the preliminary results of the OHE investigation suggest the need for standards for validating PFS as a surrogate of OS, as well as the need for clinical trial protocols that facilitate the use of PFS as a surrogate. Additionally, there was a consensus on the fact that the validity of the surrogates is affected by multiple factors such as cancer type, drug mechanism of action, phase of development, year of the trial, state of the disease.

The discussion is currently being followed up with an internet survey. In this survey, workshop participants are asked to summarise their conclusions from the workshop and describe future challenges in the validation of surrogates that should be considered. The results from the literature review, the workshop discussion as well as the posterior survey will be published by the OHE in the coming months.

For more information contact Karla Hernandez-Villafuerte at OHE.

 

  • Drug Development/R&D
  • Measuring and Valuing Outcomes
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!